Octreotide acetate

Population PK analysis following a single dose of 30 mg microencapsulated octreotide acetate intramuscularly the PK profile of microencapsulated octreotide acetate was effectively described by the derived population model. The relationship between IGF-1 and drug concentration could be used to guide optimization of therapeutic octreotide dosage regimens... 

FIG. 5. Intestinal absorption of octreotide acetate in rats using mucoadhesive polymers. (From Thanou et al. unpublished data). 

Octreotide acetate (Sandostatin) is a synthetic peptide analogue of the hormone somatostatin. Its actions include inhibition of the pituitary secretion of growth hormone and an inhibition of pancreatic islet cell secretion of insulin and glucagon. Unlike somatostatin, which has a plasma half-life of a few minutes, octreotide has a plasma elimination half-Hfe of 1 to 2 hours. Excretion of the drug is primarily renal. 

Recommended dosage and monitoring requirements Sandostatin injectable solution is usually administered subcutaneously in initial doses of 50 to 100 pg two or three times daily. Upward dose titration is frequently required. Sandostatin LAR Depot injectable suspension should never be administered intravenously or subcutaneously. Patients not currently receiving octreotide acetate should begin therapy with subcutaneous injections and then can be switched to the depot injection of 20mg intragluteally at 4-week intervals for 3 months. 

Octreotide acetate injectable long-acting suspension is a slow-release microsphere formulation. It is instituted only after a brief course of shorter-acting octreotide has been demonstrated to be effective and tolerated. Injections into alternate gluteal muscles are repeated at 4-week intervals in doses of 20-40 mg. 

Lau, D.T.W., et al. 1994. Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (Sandostatin ) in the rabbit. Pharm Res 11 1742. 

Wang, J., Wang, B. M., and Schwendeman, S. P. (2004), Mechanistic evaluation of the glucose-induced reduction in initial burst release of octreotide acetate from poly(D,L-lactide-co-glycolide) microspheres, Biomaterials, 25,1919-1927. 

ACUTE HEMORRHAGE FROM ESOPHAGEAL VARICES Octreotide Acetate... 

Rubin, J. Ajani, J. Schirmer, W. Venook, A.P. Bukowski, R. Pommier, R. Saltz, L. Dandona, P. Anthony, L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in mahgnant carcinoid syndrome. J. Clin. Oncol. 1999,17 (2), 600-606. 

Octreotide acetate 84-(Sandostatin) SC/IM/IV after dilution Lactic acid 0.34% pH 4.2... 

A powerful new synthetic peptide that mimics the action of somatostatin, octreotide acetate (Sandostatin). is approved by the Food and Drug Administration (FDA) for (he treatment of certain rare forms of intestinal endocrine cancers, such as malignant carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). Octreotide acetate is indicated for long-term treatment of severe diarrhea associated with these carcinomas. 

Octreotide acetate. X45 Ocufen. See l-lurhiprofcii Ocupa-ss. See Cartcolol Ofloxacin. 248. 2481. 2.50 Oil of wintcrgrccn. 754 OKT3. See Murom nab-CD3 Olun/apinc. 502 -50.3 Olcandolide. 353 Oleandomycin. 35.3 Olefins, oxidation of. 74 -77 2 ,5 -Oligoadenylaic synthetase. 202 Olivomycins. 417 Olsala/inc... 

---